Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Next Previous
Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Mycophenolate; Prednisone; Rituximab
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVOCATE
  • Sponsors ChemoCentryx

    • Most Recent Events

    • 18 Nov 2023 Results of subgroup analysis assessing the safety and efficacy of Avacopan in patients with ANCA-associated vasculitis receiving rituximab published in the Annals of the Rheumatic Diseases.
    • 15 Nov 2023 Results of post-hoc analysis assessing effect of avacopan on urinary albumin:creatinine ratio in patients with antineutrophil cytoplasmic autoantibody presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results evaluating the efficacy and safety of avacopan in patients in the RTX stratum , presented at the ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top